Middle East & Africa Cell Reprogramming Market Size & Outlook

The cell reprogramming market in Middle East & Africa is expected to reach a projected revenue of US$ 11.6 million by 2030. A compound annual growth rate of 7.2% is expected of Middle East & Africa cell reprogramming market from 2025 to 2030.
Revenue, 2024 (US$M)
$7.6
Forecast, 2030 (US$M)
$11.6
CAGR, 2025 - 2030
7.2%
Report Coverage
Middle East & Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Middle East & Africa cell reprogramming market, 2018-2030 (US$M)

Middle East & Africa cell reprogramming market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

MEA cell reprogramming market highlights

  • The MEA cell reprogramming market generated a revenue of USD 7.6 million in 2024.
  • The market is expected to grow at a CAGR of 7.3% from 2025 to 2030.
  • In terms of segment, episomal reprogramming was the largest revenue generating technology in 2024.
  • MRNA Reprogramming is the most lucrative technology segment registering the fastest growth during the forecast period.
  • Country-wise, UAE is expected to register the highest CAGR from 2025 to 2030.

MEA data book summary

Market revenue in 2024USD 7.6 million
Market revenue in 2030USD 11.6 million
Growth rate7.3% (CAGR from 2025 to 2030)
Largest segmentEpisomal reprogramming
Fastest growing segmentMRNA Reprogramming
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming
Key market players worldwideThermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies

Other key industry trends

  • In terms of revenue, MEA region accounted for 1.9% of the global cell reprogramming market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 169.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell Reprogramming Market Companies

Name Profile # Employees HQ Website
Alstem View profile 11-50 Richmond, Virginia, United States, North America https://www.alstembio.com/web/
Allele Biotech View profile 11-50 San Diego, California, United States, North America http://www.allelebiotech.com/
STEMCELL Technologies View profile 501-1000 Vancouver, British Columbia, Canada, North America https://www.stemcell.com
ReproCELL View profile 51-100 Yokohama, Kanagawa, Japan, Asia http://reprocell.com
Astellas Pharma Inc View profile 14484 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 http://www.astellas.com
Bio-Techne Corp View profile 3050 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 https://www.bio-techne.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
FUJIFILM Holdings Corp View profile 83784 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 http://www.fujifilmholdings.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

Middle East & Africa cell reprogramming market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.


Episomal reprogramming was the largest segment with a revenue share of 32.89% in 2024. Horizon Databook has segmented the Middle East & Africa cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.


  • Middle East & Africa Cell Reprogramming Technology Outlook (Revenue, USD Million, 2018-2030)
    • Sendai Virus-based Reprogramming
    • mRNA Reprogramming
    • Episomal Reprogramming
    • Others
  • Middle East & Africa Cell Reprogramming Application Outlook (Revenue, USD Million, 2018-2030)
    • Research
    • Therapeutic
  • Middle East & Africa Cell Reprogramming End Use Outlook (Revenue, USD Million, 2018-2030)
    • Research & Academic Institutes
    • Biotechnology & Pharmaceutical Companies

Reasons to subscribe to Middle East & Africa cell reprogramming market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa cell reprogramming market databook

  • Our clientele includes a mix of cell reprogramming market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cell reprogramming market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA cell reprogramming market size, by country, 2018-2030 (US$M)

Middle East & Africa Cell Reprogramming Market Outlook Share, 2024 & 2030 (US$M)

MEA cell reprogramming market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online